```
=> b reg
FILE 'REGISTRY' ENTERED AT 10:16:48 ON 04 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     2 AUG 2006  HIGHEST RN 898176-03-9
DICTIONARY FILE UPDATES:    2 AUG 2006  HIGHEST RN 898176-03-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d que sta l19
L12             STR

Hy---N
1   2


NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   2

STEREO ATTRIBUTES: NONE
L13       158222 SEA FILE=REGISTRY ABB=ON  PLU=ON  (NCNC2-NC5-C6 OR NCNC2-NC5
                 OR NCNC2-NC5-NC5 OR NCOC2-NC5-C6 OR NCOC2-NC5 OR NCSC2-NC5-C6
                 OR NCSC2-NC5)/ES
L14      1451827 SEA FILE=REGISTRY ABB=ON  PLU=ON  (NCOC2-NC5-NC5 OR NCSC2-NC5-N
                 C5 OR NC5-C6 OR NC5-NC5 OR NCNC2-C6 OR NCNC2-NCNC3 OR NCNC2-NCN
                 C2-NC5)/ES
L15      1606332 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L13 OR L14)
L17             SCR 1568
L19        67530 SEA FILE=REGISTRY SUB=L15 SSS FUL L12 AND L17

100.0% PROCESSED   96844 ITERATIONS                        67530 ANSWERS
SEARCH TIME: 00.00.02


=> d que sta l26
L17             SCR 1568
L24             STR
```



VAR G1=6/7/8
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L26 1194 SEA FILE=REGISTRY SSS FUL L24 AND L17

100.0% PROCESSED 53414 ITERATIONS 1194 ANSWERS
SEARCH TIME: 00.00.01

=> d que sta l35
L31 26023 SEA FILE=REGISTRY ABB=ON PLU=ON NCNC2-NC5-C6/ES
L33 STR

Cy~~Hy=N
3 1 2

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 3
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 3

STEREO ATTRIBUTES: NONE
L35 2972 SEA FILE=REGISTRY SUB=L31 SSS FUL L33

100.0% PROCESSED 26022 ITERATIONS 2972 ANSWERS
SEARCH TIME: 00.00.01

=> => d que sta l30
L12 STR

Hy=N
1 2

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 2

STEREO ATTRIBUTES: NONE

```
L17             SCR 1568
L28        4930 SEA FILE=REGISTRY ABB=ON  PLU=ON  NCSC2-NCNC3/ES AND OC4/ES
L30          27 SEA FILE=REGISTRY SUB=L28 SSS FUL L12 AND L17

100.0% PROCESSED      27 ITERATIONS                          27 ANSWERS
SEARCH TIME: 00.00.01


=> => b hcap
FILE 'HCAPLUS' ENTERED AT 10:42:18 ON 04 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 4 Aug 2006  VOL 145 ISS 6
FILE LAST UPDATED: 2 Aug 2006  (20060802/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d bib abs hitind hitstr retable l59 tot

L59  ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2006 ACS on STN
AN   2006:236816  HCAPLUS
DN   144:286177
TI   Method using toll-like receptor 8 (TLR8) agonists for stimulating the
     immune response of newborns
IN   Levy, Ofer; Wessels, Michael; Miller, Richard L.; Tomai, Mark A.
PA   Children's Medical Center Corporation, USA; 3M Innovative
     Properties Company
SO   PCT Int. Appl., 67 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO2006029223         A2    20060316    2005WO-US31904         20050908
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
             SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
             ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRAI 2004US-607833P       P     20040908
     2005US-692325P       P     20050620
```

2005US-694267P P 20050627

AB The invention is based on the surprising discovery that agonists of TLR8 are uniquely efficacious in enhancing (e.g. inducing) the immune response of newborns. Thus, agonists of TLR8 serve as both vaccine adjuvants and as adjunctive therapies for acute infection in newborns, preferably the agonist is a TLR8-selective agonist. The immune response induced, or enhanced, in the neonatal host can be, for example, a cytokine immune response and/or a humoral immune response (e.g., antigen-specific).

CC 1-7 (Pharmacology)
Section cross-reference(s): 15

IT Anti-infective agents
Antibacterial agents
Antiviral agents
Combination chemotherapy
Cord blood
Fungicides
Human
Immunostimulants
Infection
Monocyte
Neoplasm
Newborn
Parasiticides
Prophylaxis
Signal transduction, biological
Vaccines
(toll-like receptor 8 agonist for stimulating immune response of newborn)

IT 162397-26-4 256922-53-9 256922-57-3 256922-63-1 256922-65-3
256922-70-0 256922-76-6 256922-81-3 256922-82-4
878555-54-5 878555-55-6 878555-56-7 878555-57-8 878555-58-9
878555-59-0 878555-60-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(toll-like receptor 8 agonist for stimulating immune response of newborn)

IT **256922-70-0**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(toll-like receptor 8 agonist for stimulating immune response of newborn)

RN 256922-70-0 HCAPLUS
CN Thiazolo[4,5-c]quinoline-4,8-diamine, 2-propyl- (9CI) (CA INDEX NAME)



L59 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:216958 HCAPLUS
DN 144:299305
TI Compositions comprising nitrogen-containing heterocycle immune response modifiers for mucosal vaccination
IN Miller, Richard L.; Kieper, William C.
PA 3M Innovative Properties Company, USA
SO U.S. Pat. Appl. Publ., 20 pp.

CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US2006051374	A1	20060309	2005US-0116476	20050428
PRAI 2004US-566121P	P	20040428		

AB The present invention provides pharmaceutical **combinations** that include small mol. immune response modifiers (IRMs) formulated for mucosal administration and an antigen formulated for mucosal administration. Addnl., the invention provides methods for immunizing a subject. Generally, the methods include administering an antigen to a mucosal surface of the subject in an amount effective, in **combination** with an IRM compound, to generate an immune response against the antigen; and administering an IRM compound to a mucosal surface of the subject in an amount effective, in **combination** with the antigen, to generate an immune response against the antigen. For example, an ovalbumin-IRM1 (N-[6-[[2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl] 1,1-dimethylethyl]amino]-6-oxohexyl]-4-azido-2-hydroxybenzamide) conjugate was prepared and suspended in PBS to a final concentration of 5 mg/mL ovalbumin and 0.5 mg/mL IRM1. Mice were immunized on Day 0 with 100 μg of the ovalbumin-IRM1 conjugate, either intranasally or i.v. Intranasal delivery of antigen plus IRM1 generated greater total ovalbumin-specific CD8+ T cell (OT-I) nos. at Day 7 than i.v. delivery in all lymphoid tissues examined Also, intranasal delivery of IRM1 plus antigen generated greater total OT-I cell nos. at Day 7 than antigen alone, indicating a dramatic effect of the IRM in enhancing antigen specific T cell activation via that route.

INCL 424204100; 424234100; 514291000
CC 63-3 (Pharmaceuticals)
Section cross-reference(s): 15
IT 144875-48-9, IRM 4 256922-56-2, IRM 3 **642473-95-8**, IRM 2
680987-04-6, IRM 1 740809-54-5, IRM 12 845638-55-3, IRM 11
847575-77-3, IRM 9 859875-28-8, IRM 6 862844-28-8, IRM 7
863728-88-5, IRM 8 878499-79-7, IRM 5 878499-80-0, IRM 10
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising antigen and aminopyridine fused to five membered nitrogen-containing heterocycle as immune modifier for mucosal vaccination)
IT **642473-95-8**, IRM 2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising antigen and aminopyridine fused to five membered nitrogen-containing heterocycle as immune modifier for mucosal vaccination)
RN 642473-95-8 HCAPLUS
CN 1H-Imidazo[4,5-c]quinoline-1-ethanamine, 4-amino-2-(ethoxymethyl)-α,α-dimethyl- (9CI) (CA INDEX NAME)



L59 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1354875 HCAPLUS
DN 144:64394
TI Use of a compound in the treatment of sleep disorders
IN Sunderraj, Palaniswamy; Shephard, Adrian; Jones, Huw
PA Boots Healthcare International Limited, UK
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005123074	A1	20051229	2004WO-GB02330	20040601 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA---2524805	AA	20041130	2004CA-2524805	20040601 <--
AU2004319510	A1	20060105	2004AU-0319510	20040601 <--
EP---1660082	A1	20060531	2004EP-0735597	20040601 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI 2003GB-0012419	A	20030530 <--		
2004WO-GB02330	W	20040601		

AB A method is disclosed for the treatment of sleep disorders. The method involves administration of triprolidine, in **combination** with at least one further active pharmaceutical agent, for enabling an individual to wake refreshed after sleep and the method of treating such an individual with triprolidine. Use of triprolidine, in **combination** with at least one further active pharmaceutical agent, as active ingredient in the manufacture of a composition for the treatment of sleep disorders is also described. A method of treating sleep of a person suffering from a sleep disorder, which method comprises administration of an ED of triprolidine, in **combination** with at least one further active pharmaceutical agent, as active i ingredient to such a person is also described. The triprolidine is administered shortly before a person wishes to fall asleep, preferably orally and most commonly in the form of a tablet containing up to 20mg, e.g. 0.1mg, 1.25mg or 2.5mg, of the active ingredient. The triprolidine is also effective in enabling an individual to sleep more easily.

IC ICM A61K-0031/44
ICS A61P-0025/00
CC 1-12 (Pharmacology)
Section cross-reference(s): 2, 63
ST triprolidine pharmaceutical **combination** therapy sleep disorder
IT Allergy
Allergy inhibitors
Althaea officinalis
Analgesics
Anesthetics
Antacids
Anti-inflammatory agents
Antiasthmatics
Antibiotics
Antidepressants
Antidiuretics
Antihistamines
Antimigraine agents
Antitussives

Antiviral agents
Anxiety
Anxiolytics
Appetite depressants
Cartagena ipecacuanha
Coating materials
Combination chemotherapy
Common cold
Cough
Cranberry
Decongestants
Disinfectants
Eucalyptus
Glycyrrhiza
Honey
Humulus
Hyperkinesia
Hypnotics and Sedatives
Influenza
Laxatives
Lubricants
Matricaria recutita
Mucous membrane
Passiflora
Pimpinella anisum
Sleep
Sleep disorders
Squill (plant)
Tranquilizers
Valeriana
(method for treatment of sleep disorders)

IT 50-23-7, Hydrocortisone 50-78-2, Aspirin 53-86-1, Indomethacin 58-08-2, Caffeine, biological studies 59-42-7, Phenylephrine 61-68-7, Mefenamic acid 73-31-4, Melatonin 76-57-3, Codeine 86-22-6, Brompheniramine 90-82-4, Pseudoephedrine 93-14-1, Guaiphenesin 94-09-7, Benzocaine 103-90-2, Paracetamol 123-03-5, Cetylpyridinium chloride 125-71-3, Dextromethorphan 132-22-9, Chlorpheniramine 136-77-6, Hexylresorcinol 137-58-6, Lidocaine 378-44-9, Betamethasone 486-12-4, Triprolidine **522-51-0**, Dequalinium chloride 525-66-6, Propranolol 550-70-9, Triprolidine hydrochloride 616-91-1, Acetylcysteine 638-23-3, Carbocisteine 768-94-5, Amantadine 1300-94-3, Amylmetacresol 1404-88-2, Tyrothricin 1490-04-6, Menthol 4419-39-0, Beclomethasone 5104-49-4, Flurbiprofen 10102-43-9, Nitric oxide, biological studies 12041-76-8, Dichlorobenzyl alcohol 13392-28-4, Rimantadine 14838-15-4, Phenylpropanolamine 15307-79-6, Diclofenac sodium 15307-86-5, Diclofenac 15686-51-8, Clemastine 15687-27-1, Ibuprofen 18683-91-5, Ambroxol 22071-15-4, Ketoprofen 22161-81-5, Dexketoprofen 22204-53-1, Naproxen 36322-90-4, Piroxicam 36791-04-5, Tribavirin 39809-25-1, Penciclovir 50679-08-8, Terfenadine 57808-66-9, Domperidone 59277-89-3, Aciclovir 59804-37-4, Tenoxicam 71125-38-7, Meloxicam 79794-75-5, Loratadine 82410-32-0, Ganciclovir 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 87848-99-5, Acrivastine 89796-99-6, Aceclofenac 103628-46-2, Sumatriptan 104227-87-4, Famciclovir 121679-13-8, Naratriptan **124832-26-4**, Valaciclovir 139110-80-8, Zanamir 139264-17-8, Zolmatriptan 144034-80-0, Rizatriptan 154323-57-6, Almotriptan 162011-90-7, Rofecoxib 169590-42-5, Celecoxib 204255-11-8, Oseltamir phosphate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treatment of sleep disorders)

IT **522-51-0**, Dequalinium chloride **124832-26-4**, Valaciclovir
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treatment of sleep disorders)

RN 522-51-0 HCAPLUS
CN Quinolinium, 1,1'-(1,10-decanediyl)bis[4-amino-2-methyl-, dichloride (9CI)

(CA INDEX NAME)



●2 Cl⁻

RN 124832-26-4 HCAPLUS
CN L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	2001			http://www.drugs.com	
Anon	1998			http://www.netdoctor	
Feng-Jing, C	2003			US2003180352 A1	
John, S	1964			US---3146169 A	HCAPLUS
Michael, N	2001			US---6245785 B1	HCAPLUS
Mignot, E	2003			WO--03032912 A	HCAPLUS

L59 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
AN **2005:1292120** HCAPLUS
DN 144:27615
TI Pharmaceutical **combination** and method for treatment of reactive arthritis or bursitis
IN Bonner, Ernest L.; Hines, Robert
PA Ficaar, Inc., USA
SO U.S. Pat. Appl. Publ., 5 pp., Cont.-in-part of U.S. Ser. No. 54,921. CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US2005272673 A1 20051208 2005US-0096260 20050329 <--
US---6087382 A 20000711 1999US-0270962 19990317 <--
US---6465473 B1 20021015 2000US-0510704 20000222 <--
US2003055022 A1 20030320 2002US-0271117 20021015 <--
US---6765000 B2 20040720
CA---2502397 AA 20040429 2003CA-2502397 20031014 <--
WO2004034987 A2 20040429 2003WO-US32653 20031014 <--
WO2004034987 A3 20040715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU2003284231 A1 20040504 2003AU-0284231 20031014 <--
EP---1558266 A2 20050803 2003EP-0776410 20031014 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP2006503095 T2 20060126 2004JP-0545314 20031014 <--
CN---1729006 A 20060201 CN 2003-80103653 20031014 <--
US2005059640 A1 20050317 2004US-0896612 20040720 <--
US---7053073 B2 20060530
US2005137181 A1 20050623 2005US-0054921 20050209 <--
PRAI 1999US-0270962 A2 19990317 <--
2000US-0510704. A2 20000222 <--
2002US-0271117 A2 20021015 <--
2004US-0896612 A2 20040720
2005US-0054921 A2 20050209
2003WO-US32653 W 20031014 <--

AB A method for treatment of conditions in human beings associated with either or both reactive arthritis or bursitis comprising administering a **combination** of a member from each of the following groups of medications: (1) synthetic purine nucleoside analog antiviral drugs, (2) antibiotic drugs, and (3) imidazole drugs. Alternate embodiments of the invention include dual **combinations** of (A) a member of the synthetic purine nucleoside analog group of antiviral drugs and a member of the antibiotic group of drugs, (B) a member of the antibiotic group of drugs and a member of the imidazole family of drugs, and (C) a member of the synthetic purine nucleoside analog group of antiviral drugs and a member of the imidazole group of drugs. A 52 yr old male presented with complaints of bilateral knee and left wrist pain. He also noted associated morning stiffness. He was treated with minocycline hydrochloride 100 mg BID and acyclovir 400 mg BID. This resulted in significant improvement, but not total resolution of his complaints of pain and stiffness in his knees and left wrist.

IC ICM A61K-0031/7076
ICS A61K-0031/52; A61K-0031/522; A61K-0031/7048
INCL 514029000; 514045000; 514263230
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT Purine nucleosides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(analogs; pharmaceutical **combination** and method for treatment of reactive arthritis or bursitis)
IT Pain
(ankle; pharmaceutical **combination** and method for treatment of reactive arthritis or bursitis)
IT Antibiotics
(macrolide; pharmaceutical **combination** and method for treatment of reactive arthritis or bursitis)
IT Antibiotics

Antimicrobial agents
Antiviral agents
Arthritis
Human
(pharmaceutical **combination** and method for treatment of reactive arthritis or bursitis)

IT Ketolides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical **combination** and method for treatment of reactive arthritis or bursitis)

IT Antibiotics
(β-lactam; pharmaceutical **combination** and method for treatment of reactive arthritis or bursitis)

IT 443-48-1, Metronidazole 10118-90-8, Minocycline 13614-98-7, Minocycline hydrochloride 59277-89-3, Acyclovir **124832-27-5**, Valacyclovir hydrochloride
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical **combination** and method for treatment of reactive arthritis or bursitis)

IT **124832-27-5**, Valacyclovir hydrochloride
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical **combination** and method for treatment of reactive arthritis or bursitis)

RN 124832-27-5 HCAPLUS
CN L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L59 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:220118 HCAPLUS
DN 142:273978
TI Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
IN Averett, Devron R.
PA USA
SO U.S. Pat. Appl. Publ., 78 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US2005054590	A1	20050310	2004US-0931130	20040901 <--
	AU2004271972	A1	20050324	2004AU-0271972	20040901 <--
	CA---2537450	AA	20050324	2004CA-2537450	20040901 <--
	WO2005025583	A2	20050324	2004WO-US28236	20040901 <--

WO2005025583 A3 20050519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP---1667694 A2 20060614 2004EP-0782670 20040901 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
PRAI 2003US-500339P P 20030905 <--
2003US-518996P P 20031110 <--
2003US-518997P P 20031110 <--
2004WO-US28236 W 20040901
OS MARPAT 142:273978
AB This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effective amount of one or more prodrugs of TLR7 ligands for the treatment or prevention of hepatitis C viral infection. Oral administration of these TLR7 immunomodulating ligands and prodrugs thereof to a mammal provides therapeutically effective amts. and reduced undesirable side effects.
IC ICM A61K-0031/7076
ICS A61K-0031/522; A61K-0031/513; A61K-0031/4745
INCL 514043000; 514045000; 514269000; 514263380; 514292000
CC 1-5 (Pharmacology)
Section cross-reference(s): 15, 26, 33, 63
IT Hepatitis
(C; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT **Receptors**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TLR7 (**Toll**-like receptor-7); administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Antiviral agents
Combination chemotherapy
Hepatitis C virus
Human
Vomiting
(administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Drug delivery systems
(carriers; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Hemorrhage
(digestive tract; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Drug delivery systems
(excipients; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Digestive tract, disease
(hemorrhage; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)

IT Infection
(hepatitis C; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Drug delivery systems
(injections, i.v.; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Digestive tract, disease
(irritation; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Digestive tract, disease
(lesions; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Drug delivery systems
(mucosal; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Drug delivery systems
(oral; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Drug delivery systems
(parenterals; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Drug delivery systems
(prodrugs; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Drug delivery systems
(vehicles; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT Infection
(viral; administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT **533897-68-6P**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT 226908-75-4P 847453-42-3P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT 122970-40-5, Isatoribine 226907-52-4 533897-38-0 847453-35-4 847453-38-7 847453-47-8
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)
IT 85658-55-5P, 5-Bromo-4-phenylpyrimidin-2-ylamine 154379-07-4P 168430-20-4P 226908-77-6P 847453-04-7P 847453-08-1P 847453-12-7P

847453-14-9P 847453-15-0P 847453-19-4P 847453-26-3P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)

IT 124737-24-2P 533897-42-6P 533897-65-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)

IT 144875-48-9
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)

IT 847453-10-5P 847453-16-1P 847453-17-2P 847453-18-3P 847453-20-7P
847453-21-8P 847453-22-9P 847453-23-0P 847453-24-1P 847453-25-2P
847453-27-4P 847453-30-9P 847453-33-2P 847453-43-4P
847453-50-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)

IT 73-24-5D, Adenine, analogs 118-00-3D, Guanosine, analogs 289-95-2D, Pyrimidine, analogs 62160-23-0 847453-51-4 847453-52-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)

IT 77-76-9, 2,2-Dimethoxypropane 108-86-1, Bromobenzene, reactions 109-12-6, 2-Aminopyrimidine 541-41-3, Ethyl chloroformate 623-78-9, N-Ethylurethane 994-30-9, Chlorotriethylsilane 1609-47-8, Diethyl pyrocarbonate 13734-41-3 18162-48-6, tert-Butyldimethylsilyl chloride 56741-95-8 87386-81-0 91526-18-0, 4-Hydroxymethyl-5-methyl-[1,3]dioxol-2-one 99011-02-6 121288-39-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)

IT 2305-87-5P 124737-25-3P 533897-16-4P 847453-05-8P 847453-06-9P
847453-07-0P 847453-09-2P 847453-28-5P 847453-29-6P 847453-31-0P
847453-32-1P 847453-34-3P 847453-36-5P 847453-37-6P 847453-39-8P
847453-40-1P 847453-41-2P 847453-44-5P 847453-45-6P 847453-46-7P
847453-48-9P 847453-49-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)

IT 533897-68-6P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in **combination** with other agents)

RN 533897-68-6 HCAPLUS

CN L-Valine, 5'-ester with 5-amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,4H)-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 847453-27-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus with fewer side effects in combination with other agents)
RN 847453-27-4 HCAPLUS
CN L-Valine, 5'-ester with 7,8-dihydro-8-oxo-7-(2-propenyl)guanosine (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L59 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:589386 HCAPLUS
DN 141:139130
TI Vaccines comprising TLR agonist, TNF/TNF receptor agonist and antigen for inducing cellular immune response against infection or tumor
IN Noelle, Randolph J.; Ahonen, Cory L.; Kedl, Ross M.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004060319	A2	20040722	2003WO-US41796	20031230
	WO2004060319	A3	20041104		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA---2511538	AA	20040722	2003CA-2511538	20031230
US2004141950	A1	20040722	2003US-0748010	20031230
AU2003300184	A1	20040729	2003AU-0300184	20031230
EP---1578419	A2	20050928	2003EP-0800433	20031230
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP2006512391	T2	20060413	2004JP-0564947	20031230
PRAI 2002US-437398P	P	20021230		
2003WO-US41796	W	20031230		

AB The present invention provides immunostimulatory **combinations**. Generally, the immunostimulatory **combinations** include a TLR agonist, a TNF or TNF receptor agonist and an tumor antigen or viral, bacterial or parasitic antigen. The TLR agonist is an agonist of TLR1-10 e.g. IRM compound, MALP-2, LPS, polyIC, CpG or any **combination**. The TNF agonist is an agonist or antibody against CD40L, OX40 ligand, 4-1BB ligand, CD27, CD30 ligand, TNF-α, TNF-β, RANK ligand, LT-α, LT-β, GITR ligand or LIGHT. The TNF receptor agonist is an antibody or agonist of CD40, OX40, 4-1BB, CD27 ligand, CD30, TNFR2, RANK, LT-αR, LT-βR, HVEM, GITR, TROY or RELT. These immunostimulatory **combinations** are useful for inducing Th1 immune response or antigen-specific CD8+ effector and memory T cell response against infectious and neoplastic conditions.

IC ICM A61K

CC 15-2 (Immunochemistry)
Section cross-reference(s): 1, 63

IT 2382-65-2D, derivs. 24939-03-5, PolyIC 132207-04-6D, 1H-Imidazo[4,5-c]quinolin-4-amine, compds. 151751-58-5 250718-44-6, MALP-2 437383-09-0 532959-63-0 642473-39-0 **642473-95-8**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccines comprising TLR agonist, TNF/TNFR agonist and antigen for inducing cellular immune response against infection or tumor)

IT **642473-95-8**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccines comprising TLR agonist, TNF/TNFR agonist and antigen for inducing cellular immune response against infection or tumor)

RN 642473-95-8 HCAPLUS

CN 1H-Imidazo[4,5-c]quinoline-1-ethanamine, 4-amino-2-(ethoxymethyl)-α,α-dimethyl- (9CI) (CA INDEX NAME)



L59 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN

AN **2003:999374** HCAPLUS

DN 140:178153

TI Efficacy of amikacin **combinations** for nocardiosis

AU Kanemitsu, Keiji; Kunishima, Hiroyuki; Saga, Tomoo; Harigae, Hideo;

Ishikawa, Shiho; Takemura, Hiromu; Kaku, Mitsuo
CS Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan
SO Tohoku Journal of Experimental Medicine (2003), 201(3), 157-163
CODEN: TJEMAO; ISSN: 0040-8727
PB Tohoku University Medical Press
DT Journal
LA English
AB The authors isolated 5 bacterial strains from patients diagnosed as having nocardiosis. Bacterial species were identified based on the similarities in the nucleotide sequences of 168 rRNAs. 3 Of the 5 strains were identified as Nocardia asteroids, but unexpectedly other 2 were Streptomyces hygroscopicus, and Rothia dentocariosa. The latter 2 species are not members of the family Nocardiaceae. The authors investigated the susceptibilities of these 5 strains to the following 9 antimicrobial agents: trimethoprim/sulfamethoxazole (TMP/SMX), minocycline (MINO), erythromycin (EM), amikacin (AMK), cefotaxime (CTX), faropenem (FRPM), imipenem (IPM), ciprofloxacin (CPFX), and sparfloxacin (SPFX). The min. inhibitory concentration (MIC) ranges (mg/mL) were as follows: TMP-SMX, 4- > 32; MINO, 0.125-8; EM, ≤ 0.016- > 32; AMK, 1-2; CTX, 0.063- > 32; FRPM, 0.063-16; IPM, 0.125-2; CPFX, 4-32; and SPFX, 0.5-16. Moreover, the synergistic effects of AMK in **combination** with each of TMP-BMX, MINO, EM, CTX, IPM, and SPFX were investigated by checkerboard synergy testing. No antagonism was recognized for the 3 N. asteroides strains. Synergistic and additive effects were observed for the **combinations** of AMK with CTX, IPM, or SPFX.
CC 10-5 (Microbial, Algal, and Fungal Biochemistry)
IT Drug interactions
(additive; amikacin **combinations** activity against nocardiosis causing pathogens)
IT Antibacterial agents
Antibiotic resistance
Antibiotics
Nocardia asteroides
Rothia dentocariosa
Streptomyces hygroscopicus
(amikacin **combinations** activity against nocardiosis causing pathogens)
IT Antibiotics
(macrolide; amikacin **combinations** activity against nocardiosis causing pathogens)
IT Drug interactions
(synergistic; amikacin **combinations** activity against nocardiosis causing pathogens)
IT Antibiotics
(β-lactam; amikacin **combinations** activity against nocardiosis causing pathogens)
IT 114-07-8, Erythromycin 8064-90-2 13614-98-7, Minomycin 37517-28-5, Amikacin 63527-52-6, Cefotaxime 64221-86-9, Imipenem 85721-33-1, Ciprofloxacin 106560-14-9, Faropenem **110871-86-8**, Sparfloxacin
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amikacin **combinations** activity against nocardiosis causing pathogens)
IT **110871-86-8**, Sparfloxacin
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amikacin **combinations** activity against nocardiosis causing pathogens)
RN 110871-86-8 HCAPLUS
CN 3-Quinolinecarboxylic acid, 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-6,8-difluoro-1,4-dihydro-4-oxo-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ambaye, A	1997	35	847	J Clin Microbiol	HCAPLUS
Beaman, B	1998	66	4676	Infect Immun	HCAPLUS
Beaman, B	1976	134	286	J Infect Dis	MEDLINE
Broeren, S	1984	37	1298	J Clin Pathol	MEDLINE
Christine, S	1998	39	793	J Am Acad Dermatol	
Chun, J	1995	45	240	Int J Syst Bacteriol	HCAPLUS
Climo, M	1999	43	1747	Antimicrob Agents Ch	HCAPLUS
Filice, G	2000		197	Fungal Disease of th	
Gomberd, M	1983	24	810	Antimicrob Agents Ch	
Holmberg, K	1973	76	43	J Gen Microbiol	MEDLINE
Isaacson, J	1988	84	352	Am J Med	MEDLINE
Kursat, S	1997	75	370	Nephron	MEDLINE
Laurent, F	1999	37	99	J Clin Microbiol	HCAPLUS
Marchetti, O	2000	44	2373	Antimicrob Agents Ch	HCAPLUS
McNeil, M	1992	15	435	Clin Infect Dis	
Menendes, R	1997	10	1542	Eur Respir J	
Minamoto, G	1998	26	242	Clin Infect Dis	MEDLINE
Mouton, J	1999	43	2473	Antimicrob Agents Ch	HCAPLUS
National Committee for	2001			Methods for dilution	
Prigogine, T	1998	26	222	Clin Infect Dis	
Ruimy, R	1996	46	259	Int J Syst Bacteriol	MEDLINE
Steingrube, V	1995	33	3096	J Clin Microbiol	HCAPLUS
Steingrube, V	1997	35	817	J Clin Microbiol	HCAPLUS
Wallace, R	1988	32	1776	Antimicrob Agents Ch	HCAPLUS
Wallace, R	1990	28	2726	J Clin Microbiol	
Wallace, R	1991	29	2407	J Clin Microbiol	
Wilson, R	1997	35	2235	J Clin Microbiol	HCAPLUS

L59 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:991285 HCAPLUS
DN 140:53409
TI Method for treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
IN Krieg, Arthur M.
PA Coley Pharmaceutical Group, Inc., USA
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2003103586	A2	20031218	2003WO-US17733	20030605 <--
	WO2003103586	A3	20040930		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU2003243409	A1	20031222	2003AU-0243409	20030605 <--
	US2004009949	A1	20040115	2003US-0455247	20030605 <--
PRAI	2002US-386274P	P	20020605 <--		
	2003WO-US17733	W	20030605 <--		

OS MARPAT 140:53409

AB Improved methods are provided for inhibiting nucleic acid-induced immune activation and for treating autoimmune disease. The methods involve using an inhibitory nucleic acid in synergistic **combination** with a small mol. antagonist of immunostimulatory CpG nucleic acids. Inhibitory nucleic acids useful according to the invention include poly G nucleic acids. Small mol. antagonists of immunostimulatory CpG nucleic acids useful according to the invention include chloroquine and derivs. of chloroquine-like mols., including substituted 2-phenylquinolin-4-amines. It is possible that one or both of the inhibitory nucleic acid and the small mol. antagonist of immunostimulatory CpG nucleic acids may directly bind to Toll-like receptor-9 (TLR9) and/or prevent the foreign nucleic acid or host nucleic acid/immune complex from binding to TLR9, or the inhibitory effect could also come at a downstream point in the TLR9 signaling pathway.

IC ICM A61K

CC 1-7 (Pharmacology)

IT Hepatitis
(B; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT Hepatitis
(C; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT Eubacteria
(CpG-containing nucleic acids; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT Immune complexes
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CpG-containing nucleic acids; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT DNA
Nucleic acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(CpG-containing; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT **Receptors**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(TLR-9 (**Toll**-like receptor-9); treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT Blood vessel
(endothelium, cell; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9

receptor-expressing cells)
IT Inflammation
Kidney, disease
(glomerulonephritis; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)
IT Transplant and Transplantation
(graft-vs.-host reaction; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)
IT Infection
(hepatitis B; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)
IT Infection
(hepatitis C; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)
IT Oligodeoxyribonucleotides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(immunostimulatory CpG-containing; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids)
IT Hepatitis B virus
Hepatitis C virus
(infection; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)
IT Intestine, disease
(inflammatory; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)
IT Autoimmune disease
(insulin-dependent diabetes mellitus; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)
IT Diabetes mellitus
(insulin-dependent; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)
IT Mammary gland, neoplasm
(paraneoplastic autoimmune disease; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)
IT Autoimmune disease
(paraneoplastic; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)
IT Dendritic cell
(plasmacytoid; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)
IT Carcinoma
(pulmonary small-cell, paraneoplastic autoimmune disease; treating autoimmune or inflammatory diseases with **combinations** of

inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT Lung, neoplasm
(small-cell carcinoma, paraneoplastic autoimmune disease; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT Drug interactions
(synergistic; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT Lupus erythematosus
(systemic; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT Antirheumatic agents
Autoimmune disease
B cell (lymphocyte)
Human
Immunosuppressants
Macrophage
Multiple sclerosis
Rheumatoid arthritis
Signal transduction, biological
Sjogren syndrome
(treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT Oligonucleotides
Phosphorothioate oligonucleotides
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT Endothelium
(vascular, cell; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT 637060-28-7 637060-29-8 637060-30-1 637060-31-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(immunostimulatory CpG-containing oligodeoxynucleotide; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids)

IT 2382-65-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(nucleic acids containing; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT 25191-14-4, Poly G
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleic acids containing; treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT 267394-75-2, GenBank AF259262 272426-49-0, GenBank AF245704

330545-35-2, GenBank AF348140
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT 54-05-7, Chloroquine 83-89-6, Quinacrine 90-45-9D, 9-Aminoacridine, derivs. 118-42-3, Hydroxychloroquine **578-68-7D**, 4-Quinolinamine, derivs. **5855-52-7D**, 2-Phenylquinolin-4-amine, derivs. 12125-02-9, Ammonium chloride, biological studies 17090-79-8, Monensin 81552-33-2, Concanamycin B 116764-51-3, Bafilomycin A 133671-50-8 150314-42-4 194919-92-1 241817-38-9 313822-97-8 313824-07-6 313824-15-6 313824-20-3 313826-09-4 637060-08-3 637060-09-4 637060-10-7 637060-11-8 637060-12-9 637060-13-0 637060-14-1 637060-15-2 637060-16-3 637060-17-4 637060-18-5 637060-19-6 637060-20-9 637060-21-0 637060-22-1 637060-23-2 637060-24-3 637060-25-4 637060-26-5 637060-27-6, 23: PN: WO03103586 SEQID: 20 claimed DNA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

IT 637063-52-6 637063-54-8
RL: PRP (Properties)
(unclaimed nucleotide sequence; method for treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids)

IT 637063-53-7 637063-55-9
RL: PRP (Properties)
(unclaimed protein sequence; method for treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids)

IT **578-68-7D**, 4-Quinolinamine, derivs. **5855-52-7D**, 2-Phenylquinolin-4-amine, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating autoimmune or inflammatory diseases with **combinations** of inhibitory oligonucleotides and small mol. antagonists of immunostimulatory CpG nucleic acids by contacting TLR-9 receptor-expressing cells)

RN 578-68-7 HCAPLUS
CN 4-Quinolinamine (9CI) (CA INDEX NAME)



RN 5855-52-7 HCAPLUS
CN 4-Quinolinamine, 2-phenyl- (9CI) (CA INDEX NAME)




```
=> d his

     (FILE 'HOME' ENTERED AT 09:30:55 ON 04 AUG 2006)

     FILE 'HCAPLUS' ENTERED AT 09:33:52 ON 04 AUG 2006
L1             2 US2004162309/PN OR (US2004-777310 OR US2003-441179#)/AP,PRN
                 E GORDEN K/AU
L2            16 E4-6
                 E QUI X/AU
L3            13 E3-7
                 E QUI XIAOHONG/AU
                 E QUI XIAO/AU
L4             1 E3
                 E VASILAKOS J/AU
L5            30 E3-5
L6          5373 3M/CS,PA

     FILE 'REGISTRY' ENTERED AT 09:36:16 ON 04 AUG 2006

     FILE 'HCAPLUS' ENTERED AT 09:36:17 ON 04 AUG 2006
L7               TRA L1 1- RN :        68 TERMS

     FILE 'REGISTRY' ENTERED AT 09:36:17 ON 04 AUG 2006
L8            68 SEA L7
L9            66 L8 AND RSD/FA
L10            1 PURINE/CN
L11            1 PYRIMIDINE/CN
L12              STR
L13       158222 (NCNC2-NC5-C6 OR NCNC2-NC5 OR NCNC2-NC5-NC5 OR NCOC2-NC5-C6 OR
L14      1451827 (NCOC2-NC5-NC5 OR NCSC2-NC5-NC5 OR NC5-C6 OR NC5-NC5 OR NCNC2-C
L15      1606332 L13-14
L16           50 L12 SAM SUB=L15
L17              SCR 1568
L18           50 L12 AND L17 SAM SUB=L15
L19        67530 L12 AND L17 FULL SUB=L15
L20            1 L9 AND C26H31N5O4
L21          194 1819.154.1/RID AND L19
L22            2 L19,L21 AND L8-9
L23              STR
L24              STR L23
L25           46 L24 AND L17
L26         1194 L24 AND L17 FULL
                 SAV TEM L19 ROB310F0/A
                 SAV TEM L26 ROB310F1/A
L27        41839 NCSC2-NCNC3/ES
L28         4930 NCSC2-NCNC3/ES AND OC4/ES
L29            2 L12 AND L17 SAM SUB=L28
L30           27 L12 AND L17 FULL SUB=L28
L31        26023 NCNC2-NC5-C6/ES
L32              STR L12
L33              STR L32
L34           50 L33 SAM SUB=L31
L35         2972 L33 FULL SUB=L31

     FILE 'REGISTRY' ENTERED AT 10:16:48 ON 04 AUG 2006
```

```
                SAV TEM L35 ROB310F2/A
                SAV TEM L30 ROB310F3/A
L36         70780 L19,L26,L30,L35
L37            14 L36 AND L8-9

     FILE 'HCAPLUS' ENTERED AT 10:18:55 ON 04 AUG 2006
L38         35042 L36
L39            74 L38 AND L1-6
L40             3 L39 AND (COMBINA? OR COTHERAP? OR COADMIN?)
L41          1878 L38 AND (COMBINA? OR COTHERAP? OR COADMIN?)
L42               QUE PY<=2003 OR AY<=2003 OR PRY<=2003 OR PRD<=20030213 OR AD<=2
L43          1612 L41 AND L42
                  E TOLL LIKE/CT
                  E E5+ALL
                  E RECEPTORS/CT
                  E E3+ALL
L44          4871 E6+OLD,NT (L) TOLL
L45             3 L44 AND L43
L46             1 L45 AND L1-6
L47             2 L45 NOT L46
L48          1609 L43 NOT L45
L49           680 L48 AND P/DT
                  SEL AN 5-7 9
L50             4 E1-8 AND L49
                  SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 10:31:10 ON 04 AUG 2006
L51             6 E9-14
                  SEL RN 4-6
L52             3 E15-17

     FILE 'HCAPLUS' ENTERED AT 10:33:32 ON 04 AUG 2006
L53             2 L52 AND L50
L54           929 L48 NOT L49
                  SEL AN 1 5 6 15
L55             4 E18-25 AND L54
                  SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 10:39:12 ON 04 AUG 2006
L56             9 E26-34
L57             1 C19H22F2N4O3 AND L56

     FILE 'HCAPLUS' ENTERED AT 10:40:28 ON 04 AUG 2006
L58             1 L57 AND L55
L59             8 L40,L47,L53,L58

=>
```